Government ❯ Health ❯ Healthcare

Pharmaceuticals

Drug Regulation Drug Safety Drug Advertising Medication Supply Advertising Risk Management Drug Procurement Drug Pricing Regulatory Affairs FDA Medication Delivery Home Delivery Services Supplier Compliance Regulatory Programs Drug Approval Process Export Targets Drug Testing Oncology Medications 340B Program International Trade Regulatory Agencies Quality Control Supply Chain Issues Clinical Trials Manufacturing in Mexico Pharmaceutical Advertising Prescription Drugs Prescription Medications Regulatory Oversight Contract Compliance Drug Approval Adverse Effects Public Health Insulin Medicine Supply Debt Management Children's Medicine Mifepristone Pharmacy Regulations Drug Review Process Procurement Processes Medical Representatives Illegal Products Hospital Pharmacy

FDA Escalates Crackdown on Drug Ads, Moves to Close ‘Adequate Provision’ Loophole

The action follows a White House directive, signaling a return to fuller on‑air risk disclosures.

FDA Sends Mass Warnings, Seeks to End 1997 Drug Ad Rule After White House Directive

FDA Launches PreCheck to Accelerate Domestic Drug Plants

HHS Opens Applications for 340B Rebate Model Pilot

FDA Publishes Over 200 Complete Response Letters for 2020–24 Drug Applications